Precision Biosciences (DTIL) Common Equity (2018 - 2025)
Historic Common Equity for Precision Biosciences (DTIL) over the last 8 years, with Q3 2025 value amounting to $16.6 million.
- Precision Biosciences' Common Equity fell 7435.64% to $16.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.6 million, marking a year-over-year decrease of 7435.64%. This contributed to the annual value of $56.4 million for FY2024, which is 19899.26% up from last year.
- Per Precision Biosciences' latest filing, its Common Equity stood at $16.6 million for Q3 2025, which was down 7435.64% from $34.1 million recorded in Q2 2025.
- Precision Biosciences' 5-year Common Equity high stood at $103.0 million for Q2 2022, and its period low was $16.6 million during Q3 2025.
- Over the past 5 years, Precision Biosciences' median Common Equity value was $58.8 million (recorded in 2021), while the average stood at $59.2 million.
- In the last 5 years, Precision Biosciences' Common Equity skyrocketed by 19899.26% in 2024 and then plummeted by 7435.64% in 2025.
- Precision Biosciences' Common Equity (Quarter) stood at $91.2 million in 2021, then crashed by 33.71% to $60.4 million in 2022, then tumbled by 68.79% to $18.9 million in 2023, then soared by 198.99% to $56.4 million in 2024, then plummeted by 70.5% to $16.6 million in 2025.
- Its Common Equity was $16.6 million in Q3 2025, compared to $34.1 million in Q2 2025 and $49.3 million in Q1 2025.